Venetoclax for relapsed or resistant CLL/SLL after prior treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies venetoclax, a targeted medicine, for people with CLL or SLL that has come back or did not respond to prior therapy. It’s likely for patients who still need treatment and have specific genetic or treatment-history features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or SLL that has come back (relapsed) or did not improve (refractory) after at least one prior treatment
- Your CLL/SLL needs treatment based on standard criteria (based on blood, scans, or symptoms)
- If you have SLL, you must have measurable disease such as swollen lymph nodes and certain blood/bone-marrow findings
- You must be able to do daily activities fairly well (ECOG 0–2)
- Your organs must be healthy enough on blood tests (bone marrow, liver, kidneys, and clotting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.